Inclusion Criteria:  Clinical diagnosis of viral pneumonia; Clinical diagnosis of Shi-du-yun-jie Zheng (damp stagnation syndrome) according to Chinese medicine, including fever,cough,sore throat,stuffy chest,irritability and thirst,short yellow urine,constipation or loose stool,thick and greasy yellow coating,and slippery pulse; Chest CT showed signs of acute exudative pneumonia in the lungs; Over 18 years old, regardless of gender, voluntarily signed an informed consent form; Those who were hospitalized and were accompanied by fever (body temperature ≥37.3℃) and respiratory tract symptoms like cough or dyspnea, when they were enrolled.  Exclusion Criteria:  Patients that are susceptible to sensitivity or known to be allergic to the study drug; Patients whose white blood cell count ≥12×10^9 or neutrophil percentage ≥80%; Patients whose weight is less than 40 kg; Patients with respiratory failure or need mechanical ventilation; Patients with shock; Patients required to be in ICU monitoring and treatment; Patients participated in other clinical trials within 1 month; Patients with known renal impairment; Patients with any of the following laboratory parameter abnormalities during the screening period or within 24 hours before screening: ALT or AST level> 5 times the upper limit of normal range (ULN) or-ALT or AST level > 3 times ULN and total bilirubin level> 2 times ULN; Patients with immune system diseases and long-term use of immunosuppressive agents; Pregnant or breastfeeding women, or who have a positive pregnancy test during the screening period, or plan to become pregnant within 3 months after the study treatment.